Bridgeway Capital Management, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.7 - $1.07 $35,000 - $53,500	50,000 Added 71.12%	120,300 $84,000
Q4 2022 Feb 14, 2023	SELL	$0.61 - $5.06 $27,450 - $227,699	-45,000 Reduced 39.03%	70,300 $63,000
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $50,280 - $95,400	-12,000 Reduced 9.43%	115,300 $692,000
Q2 2022 Aug 15, 2022	BUY	$2.59 - $4.3 $25,900 - $43,000	10,000 Added 8.53%	127,300 $527,000
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $45,360 - $63,840	12,000 Added 11.4%	117,300 $446,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $124,500 - $187,200	-30,000 Reduced 22.17%	105,300 $474,000
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $500,762 - $790,851	110,300 Added 441.2%	135,300 $630,000
Q4 2020 Feb 16, 2021	BUY	$3.56 - $5.09 $89,000 - $127,250	25,000 New	25,000 $115,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.